当前位置: 首页 >> 检索结果
341. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
作者: Désirée van der Heijde.;Maxime Breban.;Dale Halter.;Gino DiVittorio.;Johan Bratt.;Fabrizio Cantini.;Sonja Kary.;Aileen L Pangan.;Hartmut Kupper.;Suchitrita S Rathmann.;Joachim Sieper.;Phillip J Mease.
来源: Rheumatology (Oxford). 2015年54卷7期1210-9页
Chronic pain and progressive loss of physical function with AS may adversely affect health-related quality of life (HRQoL). The objective of this study was to assess the 5-year data regarding spinal mobility, physical function and HRQoL in patients with AS who participated in the Adalimumab Trial Evaluating Long-term Efficacy and Safety for AS (ATLAS) study.
342. A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study.
作者: Peter P Cheung.;Manjari Lahiri.;Gim Gee Teng.;Anita Y N Lim.;Tang Ching Lau.;Aisha Lateef.;Anselm Mak.;Laure Gossec.;Lyn March.
来源: Rheumatology (Oxford). 2015年54卷7期1161-9页
Patients can potentially monitor disease activity of RA through self-assessed swollen joints (clinical synovitis), but reliability is poor. The objective is to evaluate the use of education by US feedback on the ability of patients to assess for clinical synovitis in RA.
343. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.
作者: Fowzia Ibrahim.;Ernest Choy.;Patrick Gordon.;Caroline J Doré.;Alan Hakim.;George Kitas.;David Isenberg.;Bridget Griffiths.;Bryan Lecky.;Kuntal Chakravarty.;John Winer.;Katalin Danko.;Robert G Cooper.;Beverley White-Alao.;David L Scott.
来源: Rheumatology (Oxford). 2015年54卷6期1050-5页
Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.
344. Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.
作者: Bridget Hodkinson.;Eustatius Musenge.;Mohammed Tikly.
来源: Rheumatology (Oxford). 2015年54卷6期1033-8页
The aim of this study was to explore the clinical utility of the clinical disease activity index (CDAI). We compared the disease control with protocolized treatment adjustment following a tight control strategy utilizing either the simplified disease activity index (SDAI) or the CDAI.
345. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials.
作者: Raymond Oppong.;Sue Jowett.;Elaine Nicholls.;David G T Whitehurst.;Susan Hill.;Alison Hammond.;Elaine M Hay.;Krysia Dziedzic.
来源: Rheumatology (Oxford). 2015年54卷5期876-83页
Evidence regarding the cost-effectiveness of joint protection and hand exercises for the management of hand OA is not well established. The primary aim of this study is to assess the cost-effectiveness (cost-utility) of these management options. In addition, given the absence of consensus regarding the conduct of economic evaluation alongside factorial trials, we compare different analytical methodologies.
346. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
作者: Claire Immediato Daïen.;Sarah Gailhac.;Rachel Audo.;Thibault Mura.;Michael Hahne.;Bernard Combe.;Jacques Morel.
来源: Rheumatology (Oxford). 2015年54卷4期601-8页
We aimed to assess the effect of tocilizumab (TCZ), an IL-6 receptor inhibitor, on B, T, NK and NKT cells in patients with RA and to study the cell type predictors of remission. We also compared NK cells in patients with RA and in controls.
347. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
作者: Victoria L Manning.;Billingsley Kaambwa.;Julie Ratcliffe.;David L Scott.;Ernest Choy.;Michael V Hurley.;Lindsay M Bearne.
来源: Rheumatology (Oxford). 2015年54卷2期302-9页
The aim of this study was to conduct a cost-utility analysis of the Education, Self-management and Upper Limb Exercise Training in People with RA (EXTRA) programme compared with usual care.
348. Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan.
作者: Jessica Meijs.;Alexandre E Voskuyl.;Joanne P J Bloemsaat-Minekus.;Madelon C Vonk.
来源: Rheumatology (Oxford). 2015年54卷2期262-9页
The aim of the study was to examine the effect of bosentan on blood flow in the hand in a subset of patients who had reduced blood flow relative to healthy subjects. Additionally, the relationship between blood flow in the hands of SSc patients and the presence of digital ulcers (DUs) was assessed.
349. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.
作者: In-Ho Song.;Kay-Geert Hermann.;Hildrun Haibel.;Christian E Althoff.;Denis Poddubnyy.;Joachim Listing.;Anja Weiß.;Ekkehard Lange.;Bruce Freundlich.;Martin Rudwaleit.;Joachim Sieper.
来源: Rheumatology (Oxford). 2015年54卷2期257-61页
The aim of this study was to assess the degree of fluctuation of osteitis on MRI during long-term treatment with etanercept (ETN) in patients with early axial SpA (axSpA) with active inflammation (osteitis) on whole-body MRI in the spine and/or the SI joints at baseline.
350. Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study.
作者: Giuseppe Germanò.;Francesco Muratore.;Luca Cimino.;Alberto Lo Gullo.;Niccolò Possemato.;Pierluigi Macchioni.;Alberto Cavazza.;Nicolò Pipitone.;Luigi Boiardi.;Carlo Salvarani.
来源: Rheumatology (Oxford). 2015年54卷3期400-4页
The aim of this study was to assess the usefulness of colour duplex sonography (CDS)-guided temporal artery biopsy (TAB) for the diagnosis of GCA in patients with suspected GCA.
351. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
作者: Bente Glintborg.;Bjorn Gudbjornsson.;Niels Steen Krogh.;Emina Omerovic.;Natalia Manilo.;Mette Holland-Fischer.;Hanne M Lindegaard.;Anne Gitte Loft.;Henrik Nordin.;Laura Johnsen.;Sussi Flejsborg Oeftiger.;Annette Hansen.;Claus Rasmussen.;Gerdur Grondal.;Arni Jon Geirsson.;Merete Lund Hetland.
来源: Rheumatology (Oxford). 2014年53卷11期2100-9页
The aim of this study was to describe dose regimens, dose escalation and clinical outcomes in TNF-α inhibitor (TNFi)-naive patients with PsA treated with infliximab in routine rheumatology care.
352. Does ultrasound-scored synovitis depend on the pharmacokinetics of subcutaneous anti-TNF agents in patients with rheumatoid arthritis?
作者: Esperanza Naredo.;Michelle Hinojosa.;Lara Valor.;Diana Hernández-Flórez.;Carmen Mata-Martínez.;Belén Serrano-Benavente.;Tamara Del Río.;Natalia Bello.;María Montoro.;Juan Carlos Nieto-González.;Carlos M González.;Francisco Javier López-Longo.;Indalecio Monteagudo.;Luis Carreño.
来源: Rheumatology (Oxford). 2014年53卷11期2088-94页
The aim of this study was to investigate the influence of the pharmacokinetics of s.c. anti-TNF agents on the grade of US-detected synovitis in RA patients.
353. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
作者: Roy Fleischmann.;Andrew S Koenig.;Annette Szumski.;Henk W Nab.;Lisa Marshall.;Eustratios Bananis.
来源: Rheumatology (Oxford). 2014年53卷11期1984-93页
The aims of this study were to investigate the short-term benefit of etanercept (ETN) + MTX vs conventional synthetic DMARDs (csDMARDs; HCQ, LEF or SSZ) + MTX in subjects with established RA. The effect of disease duration (≤2 years vs >2 years) and severity (moderate vs severe) on treatment outcomes was also assessed. Methods. Data from Asian and Latin American subjects with inadequate response to MTX were pooled from the APPEAL (ETN 25 mg biweekly + MTX or csDMARD + MTX; NCT00422227) and Latin RA (ETN 50 mg/week + MTX or csDMARD + MTX; NCT00848354) studies. Endpoints included the 28-joint DAS with ESR (DAS28-ESR) low disease activity (LDA; ≤3.2), DAS28 remission (<2.6) and HAQ score ≤0.5.
354. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
作者: Lisa K Stamp.;Rufus Turner.;Irada S Khalilova.;Mei Zhang.;Jill Drake.;Louisa V Forbes.;Anthony J Kettle.
来源: Rheumatology (Oxford). 2014年53卷11期1958-65页
The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol.
355. Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.
作者: Janet Pope.;Kyle M Walker.;Faye de Leon.;Louise Vanderhoek.;Shannon Seney.;Kelly L Summers.
来源: Rheumatology (Oxford). 2014年53卷10期1830-4页
Data from a small study testing imatinib to treat SSc were used to determine if cytokine changes were related to differences in clinical parameters to model future early phase trials pairing cytokine changes and clinical parameters.
356. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
作者: Chunde Bao.;Feng Huang.;Muhammad Asim Khan.;Kaiyin Fei.;Zhong Wu.;Chenglong Han.;Elizabeth C Hsia.
来源: Rheumatology (Oxford). 2014年53卷9期1654-63页
The aim of this study was to assess the efficacy and safety of golimumab in Chinese patients with active AS.
357. Structural deterioration of finger joints with ultrasonographic synovitis in rheumatoid arthritis patients with clinical low disease activity.
作者: Jun Fukae.;Masato Isobe.;Akemi Kitano.;Mihoko Henmi.;Fumihiko Sakamoto.;Akihiro Narita.;Takeya Ito.;Akio Mitsuzaki.;Masato Shimizu.;Kazuhide Tanimura.;Megumi Matsuhashi.;Tamotsu Kamishima.;Tatsuya Atsumi.;Takao Koike.
来源: Rheumatology (Oxford). 2014年53卷9期1608-12页
In this study we investigated the relationship between synovial vascularity (SV) and structural alteration of finger joints in patients with RA and long-term sustained clinical low disease activity (CLDA).
358. Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
作者: Olivier Bruyère.;Jean-Yves Reginster.;Nicholas Bellamy.;Roland Chapurlat.;Pascal Richette.;Cyrus Cooper.; .
来源: Rheumatology (Oxford). 2014年53卷8期1457-64页
The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.
359. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial.
作者: Graham Dinsdale.;Andrea Murray.;Tonia Moore.;Janice Ferguson.;Jack Wilkinson.;Helen Richards.;Christopher E M Griffiths.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2014年53卷8期1422-30页
Cutaneous telangiectases are a characteristic and psychologically distressing feature of SSc. Our aim was to assess the efficacy of two light-based treatments: pulsed dye laser (PDL) and intense pulsed light (IPL).
360. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
作者: Roy Fleischmann.;Bradley Kerr.;Li-Tain Yeh.;Matt Suster.;Zancong Shen.;Elizabeth Polvent.;Vijay Hingorani.;Barry Quart.;Kimberly Manhard.;Jeffrey N Miner.;Scott Baumgartner.; .
来源: Rheumatology (Oxford). 2014年53卷12期2167-74页
The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout.
|